anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217

{
  "id": "MLC-T-ONC-010560",
  "term": "anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217",
  "field": "Oncology and biomedicine",
  "definition": "A fixed dose combination of two monoclonal antibodies of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217 targets and binds to both PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.",
  "synonyms": [
    "anti-CTLA4/anti-PD1 monoclonal antibody combination BCD-217",
    "anti-CTLA-4/PD-1 monoclonal antibody combination BCD-217"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-ctla-4-anti-pd-1-monoclonal-antibody-combination-bcd-217/"
}